Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin and other accessible protein thiols represent a heterogeneous group of molecular targets defined by the presence of reactive cysteine sulfhydryl (-SH) groups. Actin is a primary component of this group because its Cys374 residue is highly nucleophilic and solvent-accessible, making it a frequent site for covalent modification by electrophilic compounds (Biochemistry, 1990). These thiol groups are essential for maintaining protein structure, regulating enzymatic activity, and facilitating redox-sensitive signaling pathways (Nature Reviews Molecular Cell Biology). Drugs such as the loop diuretic ethacrynic acid interact with these targets by acting as electrophilic Michael acceptors, forming stable covalent adducts with the sulfhydryl groups (DrugBank). This interaction leads to the disruption of the actin cytoskeleton and the inhibition of various thiol-dependent enzymes, such as glutathione S-transferase, which can result in cellular morphological changes like blebbing (Journal of Pharmacology and Experimental Therapeutics). While this mechanism is utilized for therapeutic effects in managing edema and exploring cancer sensitization, the inherent lack of specificity for a single protein poses significant safety concerns, including ototoxicity and systemic oxidative stress (StatPearls).
Covalent modification of sulfhydryl (-SH) groups on cysteine residues via Michael addition or oxidation, leading to protein dysfunction, enzymatic inhibition, and cytoskeletal disruption.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin and other accessible protein thiols.